# Artesunate

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

**EMLc** ATC codes: P01BE03

| | |
|---|---|
| **Indication** | Malaria due to Plasmodium falciparum ICD11 code: 1F40 |
| **INN** | Artesunate |
| **Medicine type** | Chemical agent |
| **List type** | Core |
| **Additional notes** | For use in the management of severe malaria |
| **Formulations** | **Parenteral > General injections > IV:** 60 mg in vial powder for injection ; 30 mg in vial powder for injection ; 120 mg in vial powder for injection<br>**Local > Rectal > Other:** 100 mg capsules (EMLc) |
| **EML status history** | First added in 1999 (TRS 895)<br>Changed in 2002 (TRS 914)<br>Changed in 2007 (TRS 946)<br>Changed in 2007 (TRS 950)<br>Changed in 2017 (TRS 1006)<br>Changed in 2025 (TRS 1064) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Wikipedia** | Artesunate |
| **DrugBank** | Artesunate |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of artesunate powder for injection 30 mg, 60 mg and 120 mg on the EML and EMLc; - the deletion of the previously listed injection formulation of artesunate from the EML and EMLc; - the deletion of 50 mg and 200 mg artesunate rectal capsules from the EML and EMLc; - the deletion of 50 mg artesunate tablets from the EML and EMLc. - the removal of footnotes regarding follow-up care and combination use.